Geneos Wealth Management Inc. Boosts Holdings in Stryker Co. (NYSE:SYK)

Geneos Wealth Management Inc. grew its holdings in shares of Stryker Co. (NYSE:SYKGet Rating) by 12.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,230 shares of the medical technology company’s stock after acquiring an additional 1,662 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Stryker were worth $4,071,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Claremont Financial Group Inc. purchased a new position in shares of Stryker during the first quarter worth approximately $25,000. Exane Derivatives purchased a new position in shares of Stryker in the first quarter worth $27,000. Princeton Global Asset Management LLC increased its stake in shares of Stryker by 1,212.5% in the first quarter. Princeton Global Asset Management LLC now owns 105 shares of the medical technology company’s stock worth $28,000 after buying an additional 97 shares during the period. Dixon Hughes Goodman Wealth Advisors LLC raised its holdings in Stryker by 10,700.0% during the 1st quarter. Dixon Hughes Goodman Wealth Advisors LLC now owns 108 shares of the medical technology company’s stock valued at $29,000 after buying an additional 107 shares during the last quarter. Finally, Holloway Wealth Management LLC bought a new stake in Stryker during the 1st quarter valued at $33,000. 76.44% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Citigroup lowered their price target on shares of Stryker from $310.00 to $280.00 in a report on Tuesday, May 17th. Robert W. Baird lowered their price target on shares of Stryker from $297.00 to $240.00 and set an “outperform” rating for the company in a report on Wednesday, July 27th. Edward Jones upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday, July 28th. Bank of America lowered shares of Stryker from a “buy” rating to a “neutral” rating in a report on Monday, July 11th. Finally, BTIG Research decreased their price objective on shares of Stryker from $244.00 to $238.00 and set a “buy” rating for the company in a report on Tuesday, September 6th. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $255.57.

Stryker Stock Up 0.8 %

NYSE:SYK opened at $231.83 on Tuesday. The firm’s 50-day moving average price is $208.94 and its 200-day moving average price is $230.30. The company has a market capitalization of $87.67 billion, a PE ratio of 42.69, a P/E/G ratio of 2.79 and a beta of 1.03. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.00 and a quick ratio of 1.15. Stryker Co. has a 1-year low of $188.84 and a 1-year high of $280.43.

Stryker (NYSE:SYKGet Rating) last released its earnings results on Tuesday, July 26th. The medical technology company reported $2.25 earnings per share for the quarter, missing analysts’ consensus estimates of $2.28 by ($0.03). Stryker had a return on equity of 23.34% and a net margin of 11.79%. During the same quarter in the previous year, the company earned $2.25 earnings per share. On average, equities analysts predict that Stryker Co. will post 9.38 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Investors of record on Friday, September 30th will be given a dividend of $0.695 per share. This represents a $2.78 annualized dividend and a yield of 1.20%. The ex-dividend date is Thursday, September 29th. Stryker’s dividend payout ratio (DPR) is 51.20%.

About Stryker

(Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Further Reading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKGet Rating).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.